UK Markets close in 14 mins
  • FTSE 100

    7,530.01
    +14.26 (+0.19%)
     
  • FTSE 250

    20,099.50
    +72.46 (+0.36%)
     
  • AIM

    922.71
    -3.96 (-0.43%)
     
  • GBP/EUR

    1.1847
    +0.0009 (+0.08%)
     
  • GBP/USD

    1.2007
    -0.0044 (-0.3650%)
     
  • BTC-GBP

    19,491.48
    -103.21 (-0.53%)
     
  • CMC Crypto 200

    557.69
    -0.04 (-0.01%)
     
  • S&P 500

    4,278.62
    +4.58 (+0.11%)
     
  • DOW

    33,930.13
    -50.19 (-0.15%)
     
  • CRUDE OIL

    90.32
    +2.21 (+2.51%)
     
  • GOLD FUTURES

    1,774.70
    -2.00 (-0.11%)
     
  • NIKKEI 225

    28,942.14
    -280.63 (-0.96%)
     
  • HANG SENG

    19,763.91
    -158.54 (-0.80%)
     
  • DAX

    13,679.01
    +52.30 (+0.38%)
     
  • CAC 40

    6,545.67
    +17.35 (+0.27%)
     

Unaudited NAV for June 2022

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
Unaudited NAV for June 2022
22-Jul-2022 / 07:00 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

 

Arix Bioscience plc

 

Unaudited NAV for June 2022

 

LONDON, 22 July 2022: Arix Bioscience plc (“Arix” or the “Company”) (LSE: ARIX), a global venture capital company focused on investing in breakthrough biotechnology companies, announces the unaudited Net Asset Value (“NAV”) of the Company for the date ended 30 June 2022 as follows:

 

Date

NAV Breakdown

Total NAV

 

NAV per share

Listed Portfolio

Unlisted Portfolio

Cash

Other Interests

30 June 22

(unaudited)

£37.5m

£56.2m

£131.1m

£2.9m

£227.7m

£1.76

 

 

[ENDS]

 

Enquiries

For more information on Arix, please contact:

 

Arix Bioscience plc

+44 (0)20 7290 1050

ir@arixbioscience.com

 

Powerscourt Group

Sarah MacLeod, Ibrahim Khalil, Nick Johnson

+44 (0)20 7250 1446

arix@powerscourt-group.com

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in breakthrough biotechnology companies around cutting-edge advances in life sciences.

 

We collaborate with exceptional entrepreneurs and provide the capital, expertise, and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:

GB00BD045071

Category Code:

MSCM

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

3.1. Additional regulated information required to be disclosed under the laws of a Member State

Sequence No.:

176430

EQS News ID:

1403557


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting